You have accessJournal of UrologyCME1 Apr 2023MP79-04 STEM-CELL, SHOCKWAVE, AND PLATELET RICH PLASMA THERAPY FOR THE TREATMENT OF ERECTILE DYSFUNCTION AND PEYRONIE’s DISEASE: A SURVEY OF CLINICS ACROSS THE US Jordan Best, Jamie Thomas, Michael Sencaj, Armin Ghomeshi, Isaac Zucker, and Ranjith Ramasamy Jordan BestJordan Best More articles by this author , Jamie ThomasJamie Thomas More articles by this author , Michael SencajMichael Sencaj More articles by this author , Armin GhomeshiArmin Ghomeshi More articles by this author , Isaac ZuckerIsaac Zucker More articles by this author , and Ranjith RamasamyRanjith Ramasamy More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003356.04AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: With the significant increase in ED and PyD practices offering off-label restorative therapy, it is imperative to investigate if these practices are providing proper patient care, clear outcome expectations for patients, and necessary safety and side effect information to patients. Our objective was to identify clinics offering off-label therapies for erectile dysfunction (ED) and Peyronie’s disease (Pyd) including stem cell, platelet rich plasma, and shockwave therapy and to determine the transparency they provided to patients inquiring about these treatment modalities. METHODS: Clinics were identified in different regions in the US using a systematic search on online website directories and were approached by asking a series of standardized questions regarding cost of treatment, duration of therapy, medical staff involved, and patient outcome data. A total of 26 clinics were surveyed for stem cell therapy, 26 for PRP treatment, and 27 for shockwave therapy. RESULTS: Of the 79 clinics contacted, 93.7% provided some answers to the questions we asked, with a majority offering treatments for both ED and Pyd. Cost of treatment varied widely between clinics. The average cost per stem cell therapy injection was $5291, PRP per injection was $1336, and shockwave therapy per session was $413. Across all clinics surveyed, a physician was involved in only 67% of treatments. Over 75% of the clinics reported patient satisfaction following treatment. Durability of benefits to patients ranged from months to years according to the clinics’ reports. CONCLUSIONS: Our data not only demonstrates the widespread use of off-label therapies for ED and PyD across the US, but also elucidates the claims and information that is being provided to patients regarding the providers involved, outcomes and safety of these treatments. This study highlights the need for more oversight and standardization in novel regenerative therapies for ED and PyD. Source of Funding: None © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e1142 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Jordan Best More articles by this author Jamie Thomas More articles by this author Michael Sencaj More articles by this author Armin Ghomeshi More articles by this author Isaac Zucker More articles by this author Ranjith Ramasamy More articles by this author Expand All Advertisement PDF downloadLoading ...
Read full abstract